Literature DB >> 26590656

The ethics of placebo controlled clinical trials in NMO - A balance of risks.

Michael Levy1.   

Abstract

Entities:  

Keywords:  Ethics; Neuromyelitis optica; Placebo-controlled trials

Mesh：

Substances：

Year:  2015        PMID： 26590656      PMCID： PMC4810439          DOI： 10.1016/j.msard.2015.07.016

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  5 in total

1.  The need to revise the Declaration of Helsinki.

Authors:  R J Levine
Journal:  N Engl J Med       Date:  1999-08-12       Impact factor: 91.245

2.  The clinical course of neuromyelitis optica (Devic's syndrome).

Authors:  D M Wingerchuk; W F Hogancamp; P C O'Brien; B G Weinshenker
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

3.  Treatment of Neuromyelitis Optica: Review and Recommendations.

Authors:  Dorlan J Kimbrough; Kazuo Fujihara; Anu Jacob; Marco A Lana-Peixoto; Maria Isabel Leite; Michael Levy; Romain Marignier; Ichiro Nakashima; Jacqueline Palace; Jérôme de Seze; Olaf Stuve; Silvia N Tenembaum; Anthony Traboulsee; Emmanuelle Waubant; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

4.  Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

Authors:  Maureen A Mealy; Dean M Wingerchuk; Jacqueline Palace; Benjamin M Greenberg; Michael Levy
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

5.  Neuromyelitis optica: an antibody-mediated disorder of the central nervous system.

Authors:  Jiwon Oh; Michael Levy
Journal:  Neurol Res Int       Date:  2012-01-29
  5 in total
  1 in total

Review 1.  Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.

Authors:  Sean J Pittock; Anastasia Zekeridou; Brian G Weinshenker
Journal:  Nat Rev Neurol       Date:  2021-10-28       Impact factor: 42.937
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.